Origin — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Origin Life Sciences is pioneering a novel drug delivery platform that converts atmospheric air into a targeted nitric oxide plasma stream for therapeutic use. The company's lead program targets diabetic foot ulcers, with a planned pivotal clinical trial as the pathway to FDA approval for the IonoJet™ device. Beyond wound care, the technology has broad potential applications across dermatology, infection control, dentistry, and respiratory conditions, positioning it as a versatile platform in the biologics and medical device space.

Wound HealingDermatologyInfectious Disease

Technology Platform

IonoJet™: A proprietary, patented high-energy plasma device that generates a therapeutic nitric oxide (NO) plasma stream from atmospheric nitrogen and oxygen for targeted delivery to treat infections, reduce inflammation, and promote tissue regeneration.

Opportunities

The primary opportunity is addressing the large, unmet need in chronic wound care, particularly diabetic foot ulcers, with a dual-action therapy that fights infection and promotes healing.

Success here could unlock a platform with expansive potential across dermatology, dentistry, infection control, and respiratory therapeutics, leveraging a novel mechanism of action.

Risk Factors

The company faces high clinical risk as its value depends on a single pivotal trial outcome.

As a pre-revenue private company, it also carries significant financial and execution risk in funding and conducting this trial.

Finally, it must navigate a competitive wound care market and prove cost-effectiveness for payer adoption.

Competitive Landscape

In wound care, Origin competes with advanced dressings, growth factor therapies, skin substitutes, and negative pressure devices. Its differentiation lies in the real-time, localized production of nitric oxide. Broader competition includes topical antibiotics and antiseptics. The platform's potential in other areas would face distinct competitive sets in each new indication.

More companies in Small Molecule Drugs →More companies in United States →